An open label, randomized study for the comparison of effectiveness between glucagon-like peptide-1 (GLP-1) analogue in people with type 2 diabetes treated bolus first or basal first insulin therapy - An open label, randomized study for the comparison of effectiveness between glucagon-like peptide-1 (GLP-1) analogue in people with type 2 diabetes treated bolus first or basal first insulin therapy

Department of Disease Control and Homeostasis,kanazawa University Graduate School of Medical Science.0 个研究点目标入组 40 人开始时间: 2013年3月29日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1.Hypersensitivity to components of liraglutide and exenatide 2.None Type 2 diabetes 3.Medical history and/or complication of diabetic ketoacidosis 4.Medical history and/or complication of severe hypoglycemia 5.Severe infection, around surgery or severe trauma 6.Patients who received the administration of DPP-4 inhibitors or GLP-1 analogue within 4 weeks 7.Treatment with glucocorticoid 8.Uncontrolled Hypertension(systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg) 9.Proliferative retinopathy or maculopathy 10.History of malignancy 11.Severe health problems not suitable for the study 12.Pregnant or lactating woman 13.Cases that Physicians deem inappropriate as the target of the test

发起方

Department of Disease Control and Homeostasis,kanazawa University Graduate School of Medical Science.